Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol

[1]  P. Gibbs,et al.  Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study , 2018, Clinical Cancer Research.

[2]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[3]  Su-Jin Shin,et al.  Feasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping , 2017, PloS one.

[4]  J. Albanell,et al.  Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. Hidalgo,et al.  Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab , 2016, Oncotarget.

[6]  G. Ribas,et al.  Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology , 2016, Oncotarget.

[7]  M. Peeters,et al.  Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. , 2015, European journal of cancer.

[8]  M. Kriegsmann,et al.  Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique , 2015, Diagnostic Pathology.

[9]  Charles Swanton,et al.  Tumour heterogeneity and the evolution of polyclonal drug resistance , 2014, Molecular oncology.

[10]  Shung-Haur Yang,et al.  Clinical Relevance of Alterations in Quantity and Quality of Plasma DNA in Colorectal Cancer Patients: Based on the Mutation Spectra Detected in Primary Tumors , 2014, Annals of Surgical Oncology.

[11]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[12]  S. Matsusaka,et al.  Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report , 2013, BMC Research Notes.

[13]  G. Fontanini,et al.  FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Jesse S. Voss,et al.  Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. , 2013, Human pathology.

[15]  S. Jeffrey,et al.  Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis , 2013, Expert review of molecular diagnostics.

[16]  A. Russo,et al.  Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[18]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[19]  E. Van Cutsem,et al.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Josep Tabernero,et al.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[22]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[23]  L. Diaz,et al.  Analysis of circulating tumor DNA to confirm somatic KRAS mutations. , 2009, Journal of the National Cancer Institute.

[24]  Frank Diehl,et al.  Detection and quantification of mutations in the plasma of patients with colorectal tumors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[26]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[27]  M. Stroun,et al.  About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[28]  S. Umansky,et al.  Circulating Nucleic Acids and Apoptosis , 2001, Annals of the New York Academy of Sciences.

[29]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[30]  J. Tabernero,et al.  Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  M. Weerts,et al.  Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases. , 2016, Molecular oncology.

[32]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[33]  A. Benson,et al.  The continuum of care: a paradigm for the management of metastatic colorectal cancer. , 2007, The oncologist.

[34]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..